# A Clinical Study With Adalimumab Biosimilar

> **NCT06291948** · PHASE1 · COMPLETED · sponsor: **Laboratorios Richmond S.A.C.I.F.** · enrollment: 150 (actual)

## Conditions studied

- Pharmacokinetics
- Safety Issues

## Interventions

- **BIOLOGICAL:** Humira® (adalimumab) AC Pen [Reference Product]
- **BIOLOGICAL:** Adalimumab Richmond [Test Product]

## Key facts

- **NCT ID:** NCT06291948
- **Lead sponsor:** Laboratorios Richmond S.A.C.I.F.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-01
- **Primary completion:** 2023-01-10
- **Final completion:** 2023-10-20
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2024-03-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06291948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06291948, "A Clinical Study With Adalimumab Biosimilar". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06291948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*